ClinicalTrials.gg
WithdrawnNCT05570188Updated Nov 30, 2022

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

A Phase 1/2 interventional study of anti-CD19 UCAR-NK cells in B-cell Lymphoma and B-cell Leukemia, sponsored by Kunming Hope of Health Hospital. Withdrawn at 1 site in China. Open to participants aged Up to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-30.

Sponsored by Kunming Hope of Health Hospital · Phase 1/2, Interventional, and Treatment

How we know

Why this study was withdrawn
The PI decides to stop.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Enrollment
265th of 273
0 · median 30
Started
2022
with 24 others
Phase 1/2
58 of 283
24 open now
Registered
148th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 265th largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2022, is one of 58 in phase 1/2, and was the 148th registered.

Lymphoma, B-Cell

889 studies on the registry are indexed under Lymphoma, B-Cell; 289 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 128 (61%) set no upper age limit and 61 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: Up to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 U-CAR-NK Cells Therapy combined with HSCT for B cell hematologic malignancies.

Read the detailed description

Who can participate? Patients who were diagnosed with B cell hematologic malignancies and tumor cells expressing CD19.

How to conduct this study? This study is an interventional clinical study. The intervention in the trial is anti-CD19 U-CAR-NK cells, which belong to chimeric antigen receptor modified NK cells. The administration time is 1-7 days after hematopoietic stem cell infusion. Patients were then evaluated for long-term efficacy and safety until 2 years after U-CAR-NK cells infusion.

What are the possible benefits and risks of participating? Benefits: The Dual effect of anti-tumor and anti-infection of NK cells may be used to promote the engraftment of hematopoietic stem cell and better disease control.

Risks: Subjects may have adverse reactions to the treatment. These adverse reactions may include abnormal liver injury, fever, thrombocytopenia, thrombotic microangiopathy, and possibly other unknown adverse reactions.

Where is the study run? Kunming Hope of Health Hospital.

03

Conditions studied

  • B-cell Lymphoma
  • B-cell Leukemia

Keywords

  • universal CAR-NK
  • Hematopoietic Stem Cell Transplantation(HSCT)
04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with indications for hematopoietic stem cell transplantation;
  2. Age ≤75 years old;
  3. Confirmed B-cell tumor and tumor cells expressing CD19;
  4. Expected survival time >12 weeks;
  5. score is 0-2;
  6. Adequate liver , kidney and cardiopulmonary function;
  7. Willingness to complete the process and to comply with study procedures and visit schedule.

Exclusion criteria

Exclusion Criteria:

  1. Had received NK cell therapy or other genetically modified cell therapy within 1 year before screening;
  2. At least 14 days or at least 5 half-lives of antitumor therapy had elapsed before screening;
  3. Patients who had undergone hematopoietic stem cell transplantation (), allogeneic hematopoietic stem cell transplantation (HSCT), or solid organ transplantation within 12 weeks before screening; Grade 2 or higher requiring therapy occurred within 2 weeks before screening;
  4. Patients with atrial or ventricular lymphoma or need urgent treatment due to tumor mass such as intestinal obstruction or vascular compression;
  5. Have received within 6 weeks before rinsing;
  6. Had a cerebrovascular accident or seizure within 6 months before screening;
  7. History of deep venous thrombosis or pulmonary embolism within 6 months before screening;
  8. A history of myocardial infarction, bypass or stent bypass, unstable angina, or other heart disease within 12 months prior to screening;
  9. Previous history of Alzheimer's disease;
  10. diseases leading to end-organ damage or requiring systemic immunosuppression (e.g. Crohns, rheumatoid arthritis, systemic lupus erythematosus) within 2 years prior to screening;
  11. There are uncontrollable infections;
  12. Women who are pregnant or breastfeeding; Or women of childbearing age who have positive pregnancy tests during the screening period; Male or female patients who did not wish to use from the time of signing the to 1 year after receiving the NK cell infusion;
  13. Conditions that other researchers deemed inappropriate for participating in the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment group

    Patients will get infused with anti-CD19 CAR-NK cells within 1 week after hematopoietic stem cell infusion.

    Biological: anti-CD19 UCAR-NK cells

Interventions

  • Biologicalanti-CD19 UCAR-NK cells

    Enrolled participants are chosen to receive one of three different dose levels of U-CAR-NK cells: Dose level one: 5-10×10\^6/kg; Dose level two:1-2×10\^7/kg; Dose level three:2-5×10\^7/kg.

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events(AE) after infusion

    The frequency, severity, and laboratory findings of all adverse events/serious adverse events are included. Description, time, classification, and outcome of AE events resulted from the investigational medical product, delivery method, or emergency measures will be recorded in the case report form.

    Time frame: Up to 12 months after infusion

Secondary outcomes

  1. Granulocyte implantation time

    Time from hematopoietic stem cell transfusion to peripheral blood granulocyte count \>0.5×10\^9/L for 3 consecutive days.

    Time frame: Up to 1 month after infusion

  2. Platelet implantation time

    Time from hematopoietic stem cell transfusion to peripheral blood platelet count \>20×10\^9/L for 7 consecutive days.

    Time frame: Up to 1 month after infusion

  3. Red blood cell implantation time

    Time from hematopoietic stem cell transfusion to peripheral blood hemoglobin count \>70g/L.

    Time frame: Up to 1 month after infusion

  4. Duration of remission (DOR)

    Duration of remission (DOR) refers to the time from the first assessment of CR or PR of the tumor to the first assessment of disease recurrence or progression or death from any cause.

    Time frame: Up to 24 weeks after infusion

  5. Disease control rate (DCR)

    Disease control rate (DCR) are defined as the percentage of patients who have achieved complete response, partial response or stable disease to a therapeutic intervention in clinical trials of anticancer agents.

    Time frame: Up to 24 weeks after infusion

  6. Overall survival (OS)

    Overall survival (OS) refers to the time from the time the patient received an infusion of CAR-NK cells until death (from any cause).

    Time frame: Up to 24 weeks after infusion

  7. Progression-free survival (PFS)

    Progression-free survival (PFS) refers to the time from the start of treatment with CAR-NK cells to the first progression of disease or death from any cause.

    Time frame: Up to 24 weeks after infusion

07

Study locations

1 site
  • Kunming Hope of Health Hospital
    Kunming, Yunnan 650000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2022 (actual). Primary completion is estimated for Oct 2024, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 6, 2022
StartActual
Oct 1, 2022
Primary completionEst.
Oct 31, 2024
CompletionEst.
Oct 31, 2025
Last update
Nov 30, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05570188
Lead sponsor
Kunming Hope of Health Hospital
Responsible party
Sponsor
First posted
Oct 6, 2022
Start date
Oct 1, 2022
Primary completion
Oct 31, 2024 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Nov 30, 2022

Study contacts

Li Li, MD
principal investigator · Kunming Hope of Health Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion